Core Viewpoint - Sanofi Pharmaceutical (01530) shares have increased by over 4%, currently trading at 31.66 HKD with a transaction volume of 940 million HKD, following the completion of a subscription agreement with Pfizer [1] Group 1: Financial Details - Sanofi Pharmaceutical announced that all conditions for the subscription agreement have been met and completed on August 1, resulting in the issuance of 31.1425 million shares at a subscription price of 25.2055 HKD per share [1] - The net proceeds from this issuance amount to approximately 785 million HKD, with 80% allocated for enhancing the global research and development pipeline for clinical and preclinical projects, and 20% for other general corporate purposes [1] Group 2: Strategic Focus - CITIC Securities released a report indicating that Pfizer is focusing on four major areas: breast cancer, urogenital system cancer, hematological cancer, and thoracic tumors, with plans to launch at least eight blockbuster oncology drugs by 2030 [1] - SSGJ-707, a dual-target antibody for PD-1 and VEGF, is well-aligned with Pfizer's core oncology treatment areas, and the company will prioritize the clinical development of SSGJ-707 in lung cancer, colorectal cancer, and breast cancer to address unmet clinical needs across multiple cancer types [1]
三生制药再涨超4% 公司完成向辉瑞配售股份 辉瑞研发战略与707开发高度适配